S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
S&P 500   3,699.12 (+0.88%)
DOW   30,218.26 (+0.83%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:TARS

Tarsus Pharmaceuticals Stock Forecast, Price & News

$24.90
+2.64 (+11.86 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$22.14
Now: $24.90
$25.32
50-Day Range N/A
52-Week Range
$15.32
Now: $24.90
$27.90
Volume46,714 shs
Average Volume69,906 shs
Market Capitalization$505.97 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Irvine, California.

Beat the Market (BTM) Rank

Analyst Opinion: 4.6Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.25 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TARS
CUSIPN/A
CIKN/A
Phone949-409-9820
Employees18

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$505.97 million
Next Earnings DateN/A
OptionableNot Optionable
$24.90
+2.64 (+11.86 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TARS News and Ratings via Email

Sign-up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tarsus Pharmaceuticals (NASDAQ:TARS) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Tarsus Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tarsus Pharmaceuticals in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Tarsus Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Tarsus Pharmaceuticals?

Wall Street analysts have given Tarsus Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tarsus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for TARS?

5 brokerages have issued 1 year price targets for Tarsus Pharmaceuticals' shares. Their forecasts range from $33.00 to $42.00. On average, they expect Tarsus Pharmaceuticals' share price to reach $37.25 in the next twelve months. This suggests a possible upside of 49.6% from the stock's current price.
View analysts' price targets for Tarsus Pharmaceuticals
.

Who are some of Tarsus Pharmaceuticals' key competitors?

Who are Tarsus Pharmaceuticals' key executives?

Tarsus Pharmaceuticals' management team includes the following people:
  • Dr. Bobak R. Azamian M.D., Pres, CEO & Director
  • Mr. Michael Holdbrook, VP of Clinical Affairs (Age 67, Pay $320.46k)
  • Mr. Leonard M. Greenstein, Chief Financial Officer (Age 44)
  • Dr. Seshadri Neervannan Ph.D., Chief Operating Officer (Age 52)
  • Ms. Maaza Martin, Director of Marketing
  • Mr. Aziz Mottiwala, Chief Commercial Officer (Age 43)
  • Ms. Kim Norman, Sr. Director of Fin.
  • Dr. Elizabeth Yeu M.D., Chief Medical Advisor

When did Tarsus Pharmaceuticals IPO?

(TARS) raised $80 million in an IPO on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James served as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers.

What is Tarsus Pharmaceuticals' stock symbol?

Tarsus Pharmaceuticals trades on the NASDAQ under the ticker symbol "TARS."

When did the company's quiet period expire?

Tarsus Pharmaceuticals' quiet period expired on Wednesday, November 25th. Tarsus Pharmaceuticals had issued 5,500,000 shares in its initial public offering on October 16th. The total size of the offering was $88,000,000 based on an initial share price of $16.00. During the company's quiet period, underwriters and any insiders involved in the IPO were restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Tarsus Pharmaceuticals?

Shares of TARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tarsus Pharmaceuticals' stock price today?

One share of TARS stock can currently be purchased for approximately $24.90.

How big of a company is Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals has a market capitalization of $505.97 million. Tarsus Pharmaceuticals employs 18 workers across the globe.

What is Tarsus Pharmaceuticals' official website?

The official website for Tarsus Pharmaceuticals is www.tarsusrx.com.

How can I contact Tarsus Pharmaceuticals?

The company can be reached via phone at 949-409-9820.

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.